Activity Overview
Generalized myasthenia gravis (gMG) is one of the most common autoimmune disorders of the neuromuscular junction. Although many patients respond to conventional immunosuppression, a substantial proportion continue to experience refractory disease or progression, and uptake of newer therapies remains a key unmet need. The treatment landscape is now expanding rapidly, with approved and investigational agents spanning B-cell–directed therapies, complement inhibition, neonatal Fc-receptor antagonism, BAFF/APRIL inhibition, and CAR-T cell approaches.
This archived recording of a CE-accredited satellite symposium presented at the 2026 Carolina Neuromuscular Diseases Summit equips neuromuscular specialists, general neurologists, and the broader care team with the resources to evaluate the latest efficacy and safety data across the emerging therapeutic landscape and gives an understanding of how these agents can be used to better design individualized treatment plans for these patients.
Target Audience
This activity is intended for neuromuscular specialists, neurologists, nurse practitioners, physician assistants, and nurses who treat neuromuscular diseases.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate emerging data on targeted therapies for gMG
- Outline the role of newer agents in the management of patients with gMG
- Design individualized multidisciplinary management plans for patients with gMG
James F. Howard Jr, MD, FAAN
Professor of Neurology, Medicine, and Allied Health
Director, Myasthenia Gravis Clinical Trials and Translational Research Program
UNC School of Medicine
The University of North Carolina at Chapel Hill
Chapel Hill, NC
Disclosures: Advisor, Consultant, Fee for Service Recipient: Alexion Pharmaceuticals, Argenx, Biologix Pharma; Grant/Research Funding: Alexion Pharmaceuticals, Argenx, Biologix Pharma, Millennium Pharmaceuticals.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.